Ratings by WBB Securities (Steve Brozak)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2025 | Celularity | CELU | Upgrade | Buy (Hold) |
2.11 (0.68) |
-67.77% | Details | |
| 8/18/2025 | Celularity | CELU | New Coverage | Speculative Buy (N/A) |
3.48 (2.11) |
-39.37% | Details | |
| 2/10/2022 | Paratek Pharmaceuticals | PRTK | Upgrade | Strong Buy (Speculative Buy) |
3.97 (2.23) |
-43.83% | Details | |
| 2/2/2022 | ContraFect Corp. | CFRX | Upgrade | Buy (Hold) |
2.93 (0.23) |
-92.15% | Details | |
| 6/18/2021 | Omeros Corp. | OMER | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/28/2021 | Redhill Biopharma | RDHL | Downgrade | Buy (Strong Buy) |
7.14 (0.90) |
-87.39% | Details | |
| 4/23/2021 | Paratek Pharmaceuticals | PRTK | Upgrade | Buy (Speculative Buy) |
7.87 (2.23) |
-71.66% | Details | |
| 3/31/2021 | ContraFect Corp. | CFRX | New Coverage | Speculative Buy (N/A) |
4.48 (0.23) |
-94.87% | Details | |
| 1/8/2020 | Paratek Pharmaceuticals | PRTK | New Coverage | Speculative Buy (N/A) |
4.15 (2.23) |
-46.27% | Details | |
| 7/12/2019 | Redhill Biopharma | RDHL | Upgrade | Strong Buy (Buy) |
6.59 (0.90) |
-86.34% | Details | |
| 3/29/2019 | Marker Therapeutics | MRKR | Upgrade | Strong Buy (Buy) |
6.71 (1.36) |
-79.73% | Details | |
| 3/12/2019 | Redhill Biopharma | RDHL | Upgrade | Buy (Speculative Buy) |
8.27 (6.59) |
-20.31% | Details |
